Zydus Lifesciences gets USFDA tentative approval for cancer drug ...
WEB1 day ago — Zydus Lifesciences share price will remain in focus on October 3 after the company received tentative approval from the United States Food and Drug Administration (USFDA) to manufacture ...
Zydus Lifesciences gets USFDA nod for prostate cancer drug
WEB21 hours ago — 3 Oct 2024 , 01:11 PM. On Wednesday, Zydus Lifesciences said that the US health regulator has given the company permission to develop a generic medication for the treatment of prostate cancer. The ...
Zydus Receives Tentative Approval from USFDA for Enzalutamide …
WEB1 day ago — Zydus Lifesciences Limited has received tentative approval from the United States Food and Drug Administration to manufacture Enzalutamide Tablets, 40 mg and 80 mg . ... Latest news about Zydus Lifesciences Limited . Zydus Lifesciences Gets Tentative Nod from US FDA for Enzalutamide Tablets 03:26am: MT ...
Zydus Lifesciences gets USFDA nod for Ahmedabad facility
WEB2 days ago — The US health regulator inspected Zydus Lifesciences’ transdermal patch manufacturing facility in Pharmez, Ahmedabad, between July 15 and July 19, the company stated in an exchange filing. The USFDA has now issued an EIR for the facility, classifying it as ‘Voluntary Action Indicated’ (VAI). Shares of Zydus Lifesciences Ltd gained nearly ...
Zydus Lifesciences receives USFDA approval to produce prostrate …
WEB1 day ago — Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to produce a generic prostate cancer treatment drug. The company has received tentative approval from the US Food and Drug Administration (USFDA) to manufacture Enzalutamide tablets (40 mg and 80 mg), the drug maker said in a …
Zydus aims to launch first new drug in US by early 2026
WEBFeb 27, 2024 — India's Zydus Lifesciences is aiming to launch its first new drug in the United States by early 2026, looking to tap into the multi-billion dollar market for treating a type of liver disease,...
Zydus ties up with CSIR-CDRI to develop drug for CKD-induced ...
WEB5 days ago — New Delhi: Zydus Lifesciences on Friday said it has tied up with Lucknow-based CSIR-Central Drug Research Institute (CDRI) to develop a drug for chronic kidney disease-induced osteoporosis. A collaborative research agreement was inked between the parties to develop oral medication through the discovery of small molecule inhibitors of Sclerostin, the Ahmedabad-based drug firm said in a ...
Zydus Lifesciences News - The Economic Times
WEB5 days ago — Zydus Lifesciences announces completion of Phase II (a) clinical trial of Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS).
Zydus receives USFDA approval for ZITUVIO™ to treat adult …
WEBOct 20, 2023 — News provided by. Zydus Lifesciences Limited. Oct 20, 2023, 10:49 ET. Share this article. The company received final approval from the USFDA for its New Drug Application (NDA) for ZITUVIO™...
India's Zydus Lifesciences Q1 profit beats estimates on strong US ...
WEBAug 9, 2024 — Indian drugmaker Zydus Lifesciences reported a bigger-than-expected first-quarter profit on Friday, driven by strong demand for its generic respiratory drugs in its key market of North America.